CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• Pernot S, Terme M, Voron T, Colussi O, Marcheteau E, Tartour E, Taieb J. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol 2014; 20(14):3738-50; PMID:24833840; http://dx.doi.org/10.3748/wjg.v20.i14.3738
   PubMed Web of Science ®Google Scholar
• Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, Karapetis CS, Pavlakis N, Sobrero AF, Cunningham D, et al. Current opinion on optimal treatment for colorectal cancer. Expert Rev Anticancer Ther 2013; 13(5):597-611; PMID:23617351; http://dx.doi.org/10.1586/era.13.37
   PubMed Web of Science ®Google Scholar
• Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O'Sullivan B, He Z, Peng Y, Tan AC, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011; 17:860-6; PMID:21725296; http://dx.doi.org/10.1038/nm.2385
   PubMed Web of Science ®Google Scholar
• Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19:57-64; PMID:23202296; http://dx.doi.org/10.1038/nm.2999
   PubMed Web of Science ®Google Scholar
• Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R, Fujii K, Ohmori H, Kuniyasu H. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer 2013; 49:741-51; PMID:23040637; http://dx.doi.org/10.1016/j.ejca.2012.09.016
   PubMed Web of Science ®Google Scholar
• Gao J, Gao J, Qian L, Wang X, Wu M, Zhang Y, Ye H, Zhu S, Yu Y, Han W. Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil. Cancer Biol Ther 2014; 15:982-91; PMID:24800927; http://dx.doi.org/10.4161/cbt.29114
   PubMed Web of Science ®Google Scholar
• Matsuyama R, Togo S, Shimizu D, Momiyama N, Ishikawa T, Ichikawa Y, Endo I, Kunisaki C, Suzuki H, Hayasizaki Y, et al. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: Three-gene expression model predicts clinical response. Int J Cancer 2006; 119:406-13; PMID:16477629; http://dx.doi.org/10.1002/ijc.21843
   PubMed Web of Science ®Google Scholar
• Pezo RC, Gandhi SJ, Shirley LA, Pestell RG, Augenlicht LH, Singer RH. Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors. Cancer Res 2008; 68:4977-82; PMID:18593893; http://dx.doi.org/10.1158/0008-5472.CAN-07-6770
   PubMed Web of Science ®Google Scholar
• O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010; 28:3937-44; PMID:20679606; http://dx.doi.org/10.1200/JCO.2010.28.9538
   PubMed Web of Science ®Google Scholar
• Vandercappellen J, Van Damme J, Struyf S. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev 2011; 22:1-18; http://dx.doi.org/10.1016/j.cytogfr.2010.10.011
   PubMed Web of Science ®Google Scholar
• Eslin DE, Zhang C, Samuels KJ, Rauova L, Zhai L, Niewiarowski S, Cines DB, Poncz M, Kowalska MA, et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis:dissociation between anticoagulant and antithrombotic effect of heparin. Blood 2004; 104(10):3173-80; PMID:14764524; http://dx.doi.org/10.1182/blood-2003-11-3994
   PubMed Web of Science ®Google Scholar
• Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Connors S, Oenick M, D'Amato RJ, Klement GL, Folkman J. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012; 15:265-73; PMID:22402885; http://dx.doi.org/10.1007/s10456-012-9259-z
   PubMed Web of Science ®Google Scholar
• Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schütte C, et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. Clin Cancer Res 2009; 15:3812-9; PMID:19470732; http://dx.doi.org/10.1158/1078-0432.CCR-08-2701
   PubMed Web of Science ®Google Scholar
• Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi A, Naumov GN, Bender E, Almog N, Italiano JE Jr, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008; 111(3):1201-7; PMID:17914028; http://dx.doi.org/10.1182/blood-2007-04-084798
   PubMed Web of Science ®Google Scholar
• Wiesner T, Bugl S, Mayer F, Hartmann JT, Kopp HG. Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis 2010; 27:141-9; PMID:20182908; http://dx.doi.org/10.1007/s10585-010-9311-6
   PubMed Web of Science ®Google Scholar
• Lam YW, Mobley JA, Evans JE, Carmody JF, Ho SM. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 2005; 5:2927-38; PMID:15952230; http://dx.doi.org/10.1002/pmic.200401165
   PubMed Web of Science ®Google Scholar
• Poruk KE, Firpo MA, Huerter LM, Scaife CL, Emerson LL, Boucher KM, Jones KA, Mulvihill SJ. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidem Biomar Prev 2010; 19:2605-10; http://dx.doi.org/10.1158/1055-9965.EPI-10-0178
   PubMed Web of Science ®Google Scholar
• Wang Z, Huang H. Platelet factor-4 (CXCL4/PF-4): an angiostatic chemokine for cancer therapy. Cancer Lett 2013; 331(2):147-53; PMID:23337289; http://dx.doi.org/10.1016/j.canlet.2013.01.006
   PubMed Web of Science ®Google Scholar
• Liang P, Cheng SH, Cheng CK, Lau KM, Lin SY, Chow EY, Chan NP, Ip RK, Wong RS, Ng MH. Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma. Haematologica 2013; 98:288-95; PMID:22929979; http://dx.doi.org/10.3324/haematol.2012.065607
   PubMed Web of Science ®Google Scholar
• Fleischer J, Grage-Griebenow E, Kasper B, Heine H, Ernst M, Brandt E, Flad HD, Petersen F. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol 2002; 169(2):770-7; PMID:12097379; http://dx.doi.org/10.4049/jimmunol.169.2.770
   PubMed Web of Science ®Google Scholar
• Liu CY, Battaglia M, Lee SH, Sun QH, Aster RH, Visentin GP. Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25− (nonregulatory) T cells. J Immunol 2005; 174:2680-6; PMID:15728475; http://dx.doi.org/10.4049/jimmunol.174.5.2680
   PubMed Web of Science ®Google Scholar
• Li JJ, Gao J, Yan D, Yuan Y, Sah S, Satyal U, Liu M, Han W, Yu Y. Neutralization of chemokine CXCL14 (BRAK) expression reduces CCl4 induced liver injury and steatosis in mice. Eur J Pharmacol 2011; 671:120-7; PMID:21978833; http://dx.doi.org/10.1016/j.ejphar.2011.09.174
   PubMed Web of Science ®Google Scholar